These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 9021406)

  • 21. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.
    May RJ; Dao T; Pinilla-Ibarz J; Korontsvit T; Zakhaleva V; Zhang RH; Maslak P; Scheinberg DA
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4547-55. PubMed ID: 17671141
    [TBL] [Abstract][Full Text] [Related]  

  • 22. NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells.
    Zarour HM; Storkus WJ; Brusic V; Williams E; Kirkwood JM
    Cancer Res; 2000 Sep; 60(17):4946-52. PubMed ID: 10987311
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Induction of EBV-latent membrane protein 1-specific MHC class II-restricted T-cell responses against natural killer lymphoma cells.
    Kobayashi H; Nagato T; Takahara M; Sato K; Kimura S; Aoki N; Azumi M; Tateno M; Harabuchi Y; Celis E
    Cancer Res; 2008 Feb; 68(3):901-8. PubMed ID: 18245493
    [TBL] [Abstract][Full Text] [Related]  

  • 24. NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells.
    Zarour HM; Maillere B; Brusic V; Coval K; Williams E; Pouvelle-Moratille S; Castelli F; Land S; Bennouna J; Logan T; Kirkwood JM
    Cancer Res; 2002 Jan; 62(1):213-8. PubMed ID: 11782380
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fine specificity of high molecular weight-melanoma-associated antigen-specific cytotoxic T lymphocytes elicited by anti-idiotypic monoclonal antibodies in patients with melanoma.
    Murray JL; Gillogly M; Kawano K; Efferson CL; Lee JE; Ross M; Wang X; Ferrone S; Ioannides CG
    Cancer Res; 2004 Aug; 64(15):5481-8. PubMed ID: 15289358
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Memory T cells of a patient with follicular thyroid carcinoma recognize peptides derived from mutated p21 ras (Gln-->Leu61).
    Gedde-Dahl T; Spurkland A; Eriksen JA; Thorsby E; Gaudernack G
    Int Immunol; 1992 Nov; 4(11):1331-7. PubMed ID: 1282032
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Persistence, immune specificity, and functional ability of murine mutant ras epitope-specific CD4(+) and CD8(+) T lymphocytes following in vivo adoptive transfer.
    Bristol JA; Schlom J; Abrams SI
    Cell Immunol; 1999 May; 194(1):78-89. PubMed ID: 10357883
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Liposomal formulations of synthetic MUC1 peptides: effects of encapsulation versus surface display of peptides on immune responses.
    Guan HH; Budzynski W; Koganty RR; Krantz MJ; Reddish MA; Rogers JA; Longenecker BM; Samuel J
    Bioconjug Chem; 1998; 9(4):451-8. PubMed ID: 9667946
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Induction of CD4(+) and CD8(+) Bordetella pertussis toxin subunit S1 specific T cells by immunization with synthetic peptides.
    Fagerberg J; Askelöf P; Wigzell H; Mellstedt H
    Cell Immunol; 1999 Sep; 196(2):110-21. PubMed ID: 10527563
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Degenerate recognition and response of human CD4+ Th cell clones: implications for basic and applied immunology.
    Nishimura Y; Chen YZ; Uemura Y; Tanaka Y; Tsukamoto H; Kanai T; Yokomizo H; Yun C; Matsuoka T; Irie A; Matsushita S
    Mol Immunol; 2004 Feb; 40(14-15):1089-94. PubMed ID: 15036913
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The inhibitory effect of altered collagen II peptide on HLA-DRB1-restricted T-cell activation.
    Cheng YJ; Zhou Q; Li ZG
    Scand J Immunol; 2005 Mar; 61(3):260-5. PubMed ID: 15787743
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
    Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
    Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthetic peptide analogs derived from bcr/abl fusion proteins and the induction of heteroclitic human T-cell responses.
    Pinilla-Ibarz J; Korontsvit T; Zakhaleva V; Roberts W; Scheinberg DA
    Haematologica; 2005 Oct; 90(10):1324-32. PubMed ID: 16219568
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Host-oriented peptide evaluation using whole blood assay for generating antigen-specific cytotoxic T lymphocytes.
    Kawabuchi Y; Yamaguchi Y; Ohshita A; Minami K; Toge T
    Anticancer Res; 2004; 24(2C):1193-200. PubMed ID: 15154646
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Binding of mutated Ras- and p53-derived peptides to HLA-DR molecules.
    Murakami S; Yokomizo H; Matsushita S; Ogawa M; Nishimura Y
    Immunol Lett; 1996 Mar; 49(3):149-53. PubMed ID: 8739309
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nonrandom catabolism of proteins in the formation of antigenic peptide fragments.
    Thomas DW; Schauster JL; Hoffman MD; Wilner GD
    J Immunol; 1985 Aug; 135(2):1259-63. PubMed ID: 3874235
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oncogene-derived peptides: a new class of tumor rejection antigens?
    Gedde-Dahl T; Olsen BH; Thorsby E; Gaudernack G
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1385-6. PubMed ID: 8442151
    [No Abstract]   [Full Text] [Related]  

  • 38. Modification of human T-cell responses by altered peptide ligands: a new approach to antigen-specific modification.
    Nishimura Y; Chen YZ; Kanai T; Yokomizo H; Matsuoka T; Matsushita S
    Intern Med; 1998 Oct; 37(10):804-17. PubMed ID: 9840700
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Successful induction of immune responses against mutant ras in melanoma patients using intradermal injection of peptides and GM-CSF as adjuvant.
    Hunger RE; Brand CU; Streit M; Eriksen JA; Gjertsen MK; Saeterdal I; Braathen LR; Gaudernack G
    Exp Dermatol; 2001 Jun; 10(3):161-7. PubMed ID: 11380611
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Binding of ras oncogene peptides to purified HLA-DQ(alpha 1*0102,beta 1*0602) and -DR(alpha,beta 1*0101) molecules.
    Johansen BH; Gedde-Dahl T; Sollid LM; Vartdal F; Thorsby E; Gaudernack G
    Scand J Immunol; 1994 Jun; 39(6):607-12. PubMed ID: 8009176
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.